Crohn's disease

Lancet

Volumn 359, Issue 9300, 2002, Pages 62-69

  Shanahan, Fergus ^a,b  

^a University College Cork and INFANT Centre   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIGEN; CYTOKINE; CYTOSOL RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BIFIDOBACTERIUM; CHROMOSOMAL LOCALIZATION; CHROMOSOME 16; CONFERENCE PAPER; CROHN DISEASE; DRUG MECHANISM; ENTEROBACTERIACEAE; ENVIRONMENTAL FACTOR; GENE CLUSTER; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HOMEOSTASIS; HUMAN; IMMUNITY; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA; LACTOBACILLUS; MEASLES VIRUS; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE INJURY; ULCERATIVE COLITIS;

EID: 0037022008     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07284-7     Document Type: Conference Paper

References (67)

1. Ulcerative colitis and Crohn's disease: Important and disabling diseases, still under-researched
2. Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics and ecotherapeutics
3. Therapy of inflammatory bowel disease
4. Enteric microflora in IBD: Pathogens or commensals?
5. Probiotics and inflammatory bowel disease: Is there a scientific rationale?
6. Commensal bacteria as targets in Crohn's disease
7. Measles virus and Crohn's disease: A critical appraisal of the current literature
8. Tuberculosis asssociated with infliximab, a tumour necrosis factor α - Neutralising agent
9. Inflammatory bowel disease and domestic hygiene in infancy
10. Mechanisms of immunologic sensation of intestinal contents
11. The genetic background of inflammatory bowel disease
12. Genetics of inflammatory bowel disease: A puzzle with contradictions?
13. Genetics of inflammatory bowel disease: A reappraisal
14. Genetics of inflammatory bowel disease
15. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
16. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
17. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations
18. Crohn's disease: Genetic susceptibility, bacteria, and innate immunity
19. NF-κB may determine whether epithelial cell-microbial interactions in the intestine are hostile or friendly
20. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease
21. Animal models of intestinal inflammation: New insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease
22. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease
23. Does the failure to acquire helminthic parasites predispose to Crohn's disease?
24. The indigenous gastrointestinal microflora
25. Epithelial cell growth and differentiation III. Promoting diversity in the intestine: Conversations between the microflora, epithelium, and diffuse GALT
26. Role of the faecal stream in the maintenance of Crohn's colitis
27. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum
28. Postoperative recurrence of Crohn's disease: The enemy is within the fecal stream
29. Characterisation of inorganic microparticles in pigment cells of human gut associated lymphoid tissue
30. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)
31. 4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease
32. The neglected organ: Bacterial flora has a crucial immunostimulatory role
33. The resident faecal flora is determined by genetic characteristics of the host: Implications for Crohn's disease?
34. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease
35. Absence of Esherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues
36. Give us this day our daily germs
37. Epithelial cells as sensors for microbial infection
38. Lipopolysaccharide activates distinct signalling pathways in intestinal epithelial cell lines expressing Toll-like receptors
39. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease
40. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria
41. Freshly isolated Peyer's Patch but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells
42. Interleukin-12 and Th1 immune responses in human Peyer's patches
43. MMPs in the gut: Inflammation hits the matrix
44. Imbalance of stromolysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease
45. A major role of matrix metalloproteinases in T cell injury in the gut
46. Suppression of T cell-mediated injury in human gut by interleukin 10: Role of matrix metalloproteinases
47. T cells in inflammatory bowel disease: Protective and pathogenic roles
48. + regulatory cells that control intestinal inflammation
49. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis
50. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance
51. Blockade of interleukin 6 trans signalling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn's disease and experimental colitis in vivo
52. Odd forms of inflammatory bowel disease - What can they tell us?
53. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
54. Pharmacogenomics and metabolite measurement of 6-mercaptopurine therapy in inflammatory bowel disease
55. Immunologic and genetic links to Crohn's disease
56. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease
57. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease
58. Infliximab for the treatment of fistulas in patients with Crohn's disease
59. Anti-TNFα therapy of rheumatoid arthritis: What have we learned?
60. CTLA4Ig-mediated blockade of T-cell co-stimulation in patients with psoriasis vulgaris
61. Patients' awareness of adverse relation between Crohn's disease and their smoking: Questionnaire survey
62. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative
63. Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination
64. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
65. Therapeutic manipulation of gut flora
66. Brain-gut axis and mucosal immunity: A perspective on mucosal psychoneuroimmunology
67. The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis